Key result
Between January and August 2023, 51 cases of Circulating Vaccine-Derived Poliovirus type 2 were documented in Nigeria, predominantly in Northwestern regions.
Highlights the re-emergence of vaccine-derived poliovirus in Nigeria, emphasizing the need for continued public health vigilance.
In August 2020, the public health landscape of Nigeria witnessed a monumental victory with the declaration of eradication of the Wild Polio Virus (WPV) by the World Health Organization (WHO).1 This milestone was particularly resonant for a nation that bore the burden of nearly half of the global polio cases in 2008. However, the recent unfolding narrative presents a contrasting picture. From January to August 2023, WHO has documented 51 cases of Circulating Vaccine-Derived Poliovirus type 2 (cVDPV2) in Nigeria, predominantly from the Northwestern regions grappling with significant insecurity.
No takes yet. Share an insight, caveat, or question.
Shehu et al. (2023) conducted an editorial in Circulating Vaccine-Derived Poliovirus type 2 (cVDPV2) (n=51). Between January and August 2023, 51 cases of Circulating Vaccine-Derived Poliovirus type 2 were documented in Nigeria, predominantly in Northwestern regions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: